Warning: The NCBI web site requires JavaScript to function. more...
Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept.
Koczan D, Drynda S, Hecker M, Drynda A, Guthke R, Kekow J, Thiesen HJ.
Arthritis Res Ther. 2008;10(3):R50. Epub 2008 May 2.
Related citations
The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
Seitz M, Wirthmüller U, Möller B, Villiger PM.
Rheumatology (Oxford). 2007 Jan;46(1):93-6. Epub 2006 May 23.
Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.
Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, Mattei JP, Nogueira L, Mugnier B, Legeron P, Landt O, Serre G, Roudier J, Roudier C.
Arthritis Rheum. 2007 Dec 15;57(8):1426-30.
Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways.
Potter C, Cordell HJ, Barton A, Daly AK, Hyrich KL, Mann DA, Morgan AW, Wilson AG; and the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate (BRAGGSS), Isaacs JD.
Ann Rheum Dis. 2010 Jul;69(7):1315-20. Epub 2010 May 6.
Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis.
Fabre S, Dupuy AM, Dossat N, Guisset C, Cohen JD, Cristol JP, Daures JP, Jorgensen C.
Clin Exp Immunol. 2008 Aug;153(2):188-95. Epub 2008 Jun 18.
Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Söderkvist P, Skogh T.
Arthritis Rheum. 2007 Feb;56(2):448-52.
Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
Park MC, Chung SJ, Park YB, Lee SK.
Scand J Rheumatol. 2008 May-Jun;37(3):173-8. Erratum in: Scand J Rheumatol. 2008 Nov-Dec;37(6):492. Jung, SJ [corrected to Chung, SJ].
Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis.
Hueber W, Tomooka BH, Batliwalla F, Li W, Monach PA, Tibshirani RJ, Van Vollenhoven RF, Lampa J, Saito K, Tanaka Y, Genovese MC, Klareskog L, Gregersen PK, Robinson WH.
Arthritis Res Ther. 2009;11(3):R76. Epub 2009 May 21.
Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
Parker A, Izmailova ES, Narang J, Badola S, Le T, Roubenoff R, Ginsburg GS, Maier A, Coblyn JS, Shadick NA, Weinblatt ME.
J Rheumatol. 2007 Sep;34(9):1817-22. Epub 2007 Aug 1.
The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis.
Kang CP, Lee KW, Yoo DH, Kang C, Bae SC.
Rheumatology (Oxford). 2005 Apr;44(4):547-52. Epub 2005 Feb 3.
Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients.
Lindberg J, af Klint E, Catrina AI, Nilsson P, Klareskog L, Ulfgren AK, Lundeberg J.
Arthritis Res Ther. 2006;8(6):R179.
Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis.
Badot V, Galant C, Nzeusseu Toukap A, Theate I, Maudoux AL, Van den Eynde BJ, Durez P, Houssiau FA, Lauwerys BR.
Arthritis Res Ther. 2009;11(2):R57. Epub 2009 Apr 23.
Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
Padyukov L, Lampa J, Heimbürger M, Ernestam S, Cederholm T, Lundkvist I, Andersson P, Hermansson Y, Harju A, Klareskog L, Bratt J.
Ann Rheum Dis. 2003 Jun;62(6):526-9.
Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients.
van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Rustenburg F, Baggen JM, Verweij CL, Tak PP.
Ann Rheum Dis. 2008 Apr;67(4):563-6. Epub 2007 Nov 27.
Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis?
Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, Zink A.
Arthritis Rheum. 2008 Mar;58(3):667-77.
Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate.
Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M.
Ann Rheum Dis. 2008 Oct;67(10):1444-7. Epub 2008 Jun 5.
[Analysis of the kinetic of expression of tristetraprolin and HuR by rheumatoid arthritis patients peripheral blood mononuclear cells stimulated with lipopolysaccharide].
Fabris M, Tolusso B, Gremese E, Tomietto P, Ferraccioli G.
Reumatismo. 2004 Apr-Jun;56(2):94-103. Italian.
Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab.
Sekiguchi N, Kawauchi S, Furuya T, Inaba N, Matsuda K, Ando S, Ogasawara M, Aburatani H, Kameda H, Amano K, Abe T, Ito S, Takeuchi T.
Rheumatology (Oxford). 2008 Jun;47(6):780-8. Epub 2008 Apr 3.
Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis.
Schotte H, Schlüter B, Willeke P, Mickholz E, Schorat MA, Domschke W, Gaubitz M.
Rheumatology (Oxford). 2004 Aug;43(8):960-4. Epub 2004 Mar 16.
Effect of discontinuing TNFalpha antagonist therapy in patients with remission of rheumatoid arthritis.
Brocq O, Millasseau E, Albert C, Grisot C, Flory P, Roux CH, Euller-Ziegler L.
Joint Bone Spine. 2009 Jul;76(4):350-5. Epub 2009 Apr 11.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on